Why Saravir?
Revolutionizing Measles Treatment and Prevention with Targeted Antibody Therapy
Saravir’s unique antibodies bind a part of the virus that prevents the virus from entering cells. Some of these antibodies neutralize the virus and are not the same antibodies generated by vaccination. These antibodies so far have not shown any predilection to resistance.
Saravir’s Competitive Advantage
First mAb combination therapy specifically for measles that targets unique fusion portion of the virus
Flexible and scalable for outbreak control
Is not a vaccine or dependent on host immunity
Likely to be protective for months
Antibodies targeting fusion protein of virus that are not observed with vaccination
Does not show any in-vitro resistance
Saravir’s Monoclonal Antibody Approach Positioned to Address the Unmet Need
The Need: An Improved Treatment and Preventative for Measles
Current approaches are unlikely to be effective if measles becomes endemic.
Commonly used treatments include:
-
Vitamin A treatment only works in Vitamin A-deficient individuals
-
Post-Exposure Prophylaxis (PEP) with immune globulin is sometimes used in case of MV exposure
Post-exposure prophylaxis
Human immunoglobulin | Approved for post-exposure treatment and works validating our approach
BUT has many shortcomings
-
Varying neutralizing activity
-
Short-livedprotection
-
Declining titers in the human population
1
2
3
Monoclonal Antibody Therapies Are Safe and Effective for Respiratory Viral Infections
Millions of antibody doses administered to treat COVID SARS CoV2 mAbs lost effectiveness against new variants.
-
Measles is less variable than SARS CoV2 (50-year-old vaccine still effective)
-
Monoclonal antibody therapies are now used to protect pregnant women and newborns against Respiratory Syncytial Virus (RSV)
4
5,6
A New Approach for a Persistent Threat
Traditional vaccines rely on host immunity. Our therapy provides a new tool in outbreak control, especially critical for vulnerable populations.
Saravir’s Antibodies Bind and Neutralize the Measles Virus
Saravir’s unique antibodies bind a part of the virus that prevents the virus from entering cells.
These antibodies neutralize the virus and are some are not the same antibodies generated by vaccination.
These antibodies so far have not shown any predilection to resistance.
Sources:
1. Infectious Diseases In Clinical Practice: Vitamin A for the Management of Measles in the United States
2. GammaStan: Product website
3. Vaccine: Post-exposure prophylaxis for the prevention of measles: A systematic review
4. CDC: History of Measles
5. Sanofi: Beyfortus product approval press release (07/17/2023)
6. Merck: ENFLONSIA approval press release (06/09/2025)
7. Zyla et all, Science 384, 1423 (2024